PPF3 vs placebo in children and teens with autism
Official title: A Randomized Placebo-Controlled TRIal of PPF3 vs. PlaCEbo in the TReatment of Children and AdolescenTs With NeurOdeveloPmental DisorderS- The TRICERATOPS Study
Run by Holland Bloorview Kids Rehabilitation Hospital · NCT07893964 · Data updated 2026-11-12
This trial tests whether PPF3 helps improve symptoms in children and adolescents with autism compared to placebo.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 8 Years to 17 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Holland Bloorview Kids Rehabilitation Hospital Academic / other |
| Locations | 4 sites (Hamilton, Ontario and 3 other locations) |
| Status | Recruiting |
| Started | October 2026 |
| Main results expected | October 2028 |
| Study ends | October 2028 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT07893964 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are outpatients aged 8-17 with ASD (DSM-5 confirmed, ADOS-2 supported), weight ≥ 30 kg, previously in the POND cohort, and stable on any current medications with consent for birth control for sexually active females of childbearing potential.
✕Probably not a fit
Patients not benefiting could include those who do not respond to PPF3 or who experience adverse effects that outweigh potential benefits.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 2 randomized, placebo-controlled trial examining the effect of PPF3 in individuals aged 8 to 17 with autism spectrum disorder who weigh at least 30 kg and have previously participated in the POND cohort. Participants are outpatients and must meet DSM-5 criteria for ASD, with confirmation by ADOS-2, and have a CGI-S score of at least 4. Stable concomitant medications are allowed if unchanged for the prior month (six weeks for fluoxetine). The study is conducted across multiple Ontario sites, with Holland Bloorview Kids Rehabilitation Hospital as lead sponsor and support from the Ontario Brain Institute and Purposeful.
Why it matters
Potential benefit: If successful, participants may experience improvements in symptoms or functioning related to autism.
How similar studies have gone: Previous studies in related neurodevelopmental targets have shown mixed results; this trial tests a novel intervention in a pediatric ASD population.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Outpatients 8-17 years of age, inclusive, with a weight ≥ 30 kg. * Already have participated in POND cohort * Females of childbearing potential who are sexually active and agree to use medically acceptable birth control throughout the study and at least one week post last dose of study drug. * Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria (American Psychiatric Association, 2013) for ASD. Diagnosis will be supported by the ADOS-2. Diagnostic and Statistical Manual (DSM-5) criteria will be established by a clinician with expertise with individuals with ASD. * Have a Clinical Global Impression-Severity (CGI-S; Guy, 1976)) score ≥ 4 (moderately ill) * If already receiving interventions, must meet the following criteria: * If receiving concomitant medications affecting behaviour, must be on a stable dose during the month prior to screening (6 weeks for Fluoxetine) and will not electively modify ongoing medications for the study duration. b. If already receiving stable non-pharmacological behavioural interventions, have stable participation during 3 months prior to screening, and will not electively modify ongoing interventions. * Have a negative pregnancy test at screening for patients who have experienced menarche * Have normal physical examination and laboratory test results at Screening. If abnormal, the finding(s) must be deemed clinically insignificant by the Qualified Investigator. Ability to obtain written informed consent from the participant, if developmentally appropriate. If a participant does not have the capacity to consent, ability to obtain assent (if developmentally appropriate), as well as written informed consent from their parent(s)/legal guardian. Exclusion Criteria: Please contact the site for details
Where it's running
-
Holland Bloorview Kids Rehabilitation Hospital
Toronto, Ontario, Canada Recruiting -
McMaster University
Hamilton, Ontario, Canada Not yet recruiting -
Queen's University
Kingston, Ontario, Canada Not yet recruiting -
London Health Sciences Centre
London, Ontario, Canada Not yet recruiting
Study contacts
- Principal investigator: Evdokia Anagnostou, MD — Holland Bloorview Kids Rehabilitation Hospital
- Study coordinator: Ches Souru, MD
- Email: csouru@hollandbloorview.ca
- Phone: 416-425-6220
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gut barrier and gut microbes in children with autism
This trial will test whether a one-month course of postbiotic supplements can improve gut symptoms and behavior in children with autism aged 3–8.
-
Follow-up of adolescents with autism and psychotic symptoms in Sweden
We are seeing if teens with autism who report psychotic symptoms still show functional impairments and psychiatric symptoms years later.
-
CRUSH curriculum for romance and sexual health for autistic young adults
This project will try the CRUSH program—a group course plus one-to-one coaching—to teach sexual health and dating skills to autistic adults ages 18 to 30.
-
Virtual reality to improve emotion understanding in children with autism
This project will test whether an Oculus virtual-reality program helps children with autism better recognize and understand emotions compared with a traditional intervention.
-
Mobile multidisciplinary pain management program for children and young adults with intellectual disability, autism, or multiple disabilities
This project will try a mobile multidisciplinary team approach to improve how pain is identified and treated for children and young adults (0–24) with intellectual disability, autism, or multiple disabilities.
-
Technology to promote healthy lifestyles in young people with intellectual disabilities
This project will try a smartphone-based program with families and teachers to help children and young adults with intellectual disabilities move more and eat healthier.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.